文献速递心律失常心力衰竭与心肌病

肾素-血管紧张素-醛固酮系统阻滞降低肥厚型心肌病心房颤动风险

Renin-angiotensin-aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy.
PubMed 文献 · Heart · 2018-01-25

结果显示,服用ACEI或ARB者新发房颤风险低于未服用者(3.16% vs 5.65%,相对风险0.56,95%CI 0.49-0.64;HR 0.572,95%CI 0.480-0.683),且治疗时间越长相关性越显著(T1至T3的HR分别为0.741、0.579、0.337,P<0.001)。

要点

  • 肥厚型心肌病患者服用ACEI或ARB与新发房颤风险降低相关。
  • ACEI/ARB治疗时间越长,新发房颤风险降低越显著。
  • 倾向评分匹配和多因素Cox回归后结果仍一致。

核心结论

  • 在肥厚型心肌病患者中,使用ACEI或ARB者较未使用两者者新发房颤风险更低。

研究设计与样本

  • 采用倾向评分匹配和多因素Cox风险回归估计新发房颤风险。

主要发现

  • 服用ACEI或ARB者新发房颤发生率为3.16%,未服用者為5.65%。
  • 相对风险为0.56(95%CI 0.49-0.64),HR为0.572(95%CI 0.480-0.683)。
  • 治疗时间越长相关性越显著,T1至T3的HR分别为0.741、0.579、0.337(P<0.001)。
  • 倾向评分调整后结果保持一致。

临床怎么用

  • 对于肥厚型心肌病患者,可考虑使用ACEI或ARB以降低新发房颤风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Atrial fibrillation (AF) in hypertrophic cardiomyopathy (HCM) is associated with increased mortality, mainly mediated by increased thromboembolic events and progressive heart failure. Many studies suggested inhibition of renin-angiotensin-aldosterone system (RAAS) could reduce new AF in various clinical conditions. However, evidence concerning the effects of RAAS inhibitors on AF prevention remains unclear in HCM. Our study is to investigate whether treatment with ACE inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) could lower the risk of new AF in HCM. METHODS: We conducted a retrospective study including subjects diagnosed HCM between January 1997 and December 2013 by using a nationwide database covering almost all Taiwanese from National Health Research Institute. All participants, aged 18 or older, had no ACEIs or ARBs exposure or AF diagnosis before enrolment. Propensity score matching and multivariate Cox hazard regression were employed to estimate the risk of new AF occurrence. RESULTS: Total 18 266 subjects were included in the analysis with median follow-up duration 8.13 years. Patients taking ACEIs or ARBs are associated with lower risk of developing new AF than those without taking neither of medications (3.16% vs 5.65%, relative risk 0.56 (95% CI 0.49 to 0.64), HR 0.572 (95% CI 0.480 to 0.683)). The correlation is more prominent with longer ACEIs or ARBs treatment (HRs from T1 to T3: 0.741, 0.579, 0.337, P<0.001). These results remain consistent after propensity score adjustment. CONCLUSION: In patients with HCM, lower risk of new AF is observed in patients treated with either ACEIs or ARBs compared with those receiving neither of these medications.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Huang CY, Yang YH, Lin LY, et al. Renin-angiotensin-aldosterone blockade reduces atrial fibrillation in hypertrophic cardiomyopathy. Heart. 2018. PMID: 29371376. doi:10.1136/heartjnl-2017-312573

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。